Expert Interview
Discussing Lilly's QWINT-1 and QWINT-3 Phase 3 data evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes
Ticker(s): LLYInstitution: Premier Endocrinology
- Private practice endocrinologist at Premier Endocrinology.
- Manages 100-200 patients with obesity and type 2 diabetes.
Roughly how many patients do you manage with type 2 diabetes?
Added By: nikki_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for efsitora alfa (efsitora)?
Added By: nikki_adminCan you share your professional background and details about your clinical practice, including how many patients you treat for type 2 diabetes?
What are your thoughts on the role of insulin in treating type 2 diabetes today, and how do new medications like GLP-1 agonists impact the need for insulin?
What do you think about the concept of long-acting insulins like efsitora alfa, and how do you interpret the trial results showing non-inferior A1C reductions compared to daily insulin glargine?
How do you view the risks of hypoglycemia with efsitora alfa, particularly in light of the QWINT-1 and QWINT-3 trial results showing varying hypoglycemia rates?
Added By: catalin_adminIf approved, how do you see efsitora alfa fitting into real-world diabetes management, and what percentage of patients might you switch or start on this weekly insulin versus daily options?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
